NASDAQ:ALZN Alzamend Neuro (ALZN) Stock Price, News & Analysis $2.48 +0.14 (+5.74%) As of 01:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Alzamend Neuro Stock (NASDAQ:ALZN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Alzamend Neuro alerts:Sign Up Key Stats Today's Range$2.31▼$2.4750-Day Range$2.20▼$3.5352-Week Range$2.06▼$31.40Volume42,587 shsAverage Volume681,289 shsMarket Capitalization$7.21 millionP/E RatioN/ADividend YieldN/APrice Target$45.00Consensus RatingBuy Company Overview Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. Read More Alzamend Neuro Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreALZN MarketRank™: Alzamend Neuro scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAlzamend Neuro has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAlzamend Neuro has only been the subject of 1 research reports in the past 90 days.Read more about Alzamend Neuro's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Alzamend Neuro are expected to decrease in the coming year, from ($1.68) to ($1.71) per share.Price to Book Value per Share RatioAlzamend Neuro has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Alzamend Neuro's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.69% of the float of Alzamend Neuro has been sold short.Short Interest Ratio / Days to CoverAlzamend Neuro has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alzamend Neuro has recently increased by 79.55%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlzamend Neuro does not currently pay a dividend.Dividend GrowthAlzamend Neuro does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.69% of the float of Alzamend Neuro has been sold short.Short Interest Ratio / Days to CoverAlzamend Neuro has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alzamend Neuro has recently increased by 79.55%, indicating that investor sentiment is decreasing significantly. News and Social Media0.9 / 5News Sentiment-0.34 News SentimentAlzamend Neuro has a news sentiment score of -0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Alzamend Neuro this week, compared to 0 articles on an average week.Search InterestOnly 5 people have searched for ALZN on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Alzamend Neuro to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Alzamend Neuro insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $627,895.00 in company stock.Percentage Held by Insiders30.21% of the stock of Alzamend Neuro is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions49.61% of the stock of Alzamend Neuro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alzamend Neuro's insider trading history. Receive ALZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter. Email Address ALZN Stock News HeadlinesMilton C. Ault III Sells 29,449 Shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) StockAugust 2, 2025 | insidertrades.comInsider Selling: Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Sells 8,311 Shares of StockJuly 30, 2025 | insidertrades.comTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.August 22 at 2:00 AM | Porter & Company (Ad)Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton C. Ault III Sells 9,621 SharesJuly 26, 2025 | insidertrades.comAscendiant Capital Markets Has Lowered Expectations for Alzamend Neuro (NASDAQ:ALZN) Stock PriceAugust 22 at 3:15 AM | americanbankingnews.comAlzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Up 79.6% in JulyAugust 19 at 2:13 AM | americanbankingnews.comAlzamend Neuro Increases Common Stock Through ConversionAugust 1, 2025 | tipranks.comAlzamend Neuro to Present at the 2025 Military Health System Research SymposiumJuly 28, 2025 | globenewswire.comSee More Headlines ALZN Stock Analysis - Frequently Asked Questions How have ALZN shares performed this year? Alzamend Neuro's stock was trading at $10.44 at the start of the year. Since then, ALZN stock has decreased by 76.5% and is now trading at $2.4550. How were Alzamend Neuro's earnings last quarter? Alzamend Neuro, Inc. (NASDAQ:ALZN) announced its quarterly earnings data on Monday, March, 10th. The company reported ($1.71) EPS for the quarter, topping the consensus estimate of ($2.61) by $0.90. When did Alzamend Neuro's stock split? Shares of Alzamend Neuro reverse split before market open on Tuesday, July 16th 2024.The 1-10 reverse split was announced on Tuesday, July 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Alzamend Neuro IPO? Alzamend Neuro (ALZN) raised $12 million in an initial public offering on Tuesday, June 15th 2021. The company issued 2,500,000 shares at $5.00 per share. Spartan Capital Securities, LLC acted as the underwriter for the IPO and -- was co-manager. How do I buy shares of Alzamend Neuro? Shares of ALZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alzamend Neuro own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alzamend Neuro investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), Predictive Oncology (POAI), AST SpaceMobile (ASTS), NIO (NIO) and Ford Motor (F). Company Calendar Last Earnings3/10/2025Today8/22/2025Next Earnings (Estimated)9/10/2025Fiscal Year End4/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALZN CIK1677077 Webwww.alzamend.com Phone844-722-6303FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Price Target for Alzamend Neuro$45.00 High Price Target$45.00 Low Price Target$45.00 Potential Upside/Downside+1,814.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.51 million Net MarginsN/A Pretax MarginN/A Return on Equity-181.34% Return on Assets-116.84% Debt Debt-to-Equity RatioN/A Current Ratio6.58 Quick Ratio6.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.95 per share Price / Book0.47Miscellaneous Outstanding Shares2,900,000Free Float2,021,000Market Cap$6.82 million OptionableNo Data Beta-0.32 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:ALZN) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.